TherapeuticsMD, Inc. (NASDAQ:TXMD) has received an average rating of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $15.29.
TXMD has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price objective on shares of TherapeuticsMD in a report on Tuesday, August 15th. Morgan Stanley initiated coverage on TherapeuticsMD in a report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price objective on the stock. Jefferies Group LLC restated a “buy” rating and set a $15.00 price objective on shares of TherapeuticsMD in a report on Friday, August 11th. Oppenheimer Holdings, Inc. set a $10.00 price target on TherapeuticsMD and gave the company a “buy” rating in a report on Monday. Finally, Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Thursday, July 13th.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/therapeuticsmd-inc-txmd-given-consensus-rating-of-buy-by-brokerages.html.
In other news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction dated Wednesday, August 30th. The stock was acquired at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the acquisition, the director now owns 3,555 shares of the company’s stock, valued at $21,294.45. The acquisition was disclosed in a filing with the SEC, which is available at this link. 23.92% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in TherapeuticsMD by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 22,892,018 shares of the company’s stock worth $120,642,000 after buying an additional 2,574,120 shares during the last quarter. JPMorgan Chase & Co. grew its stake in TherapeuticsMD by 14.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,687,509 shares of the company’s stock worth $82,674,000 after buying an additional 1,961,656 shares during the last quarter. Vanguard Group Inc. grew its stake in TherapeuticsMD by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after buying an additional 429,211 shares during the last quarter. State Street Corp grew its stake in TherapeuticsMD by 14.9% during the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after buying an additional 583,094 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in TherapeuticsMD by 33.4% during the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after buying an additional 741,588 shares during the last quarter. Hedge funds and other institutional investors own 71.57% of the company’s stock.
TherapeuticsMD (NASDAQ:TXMD) opened at 4.80 on Thursday. The stock’s market capitalization is $979.33 million. TherapeuticsMD has a 52 week low of $4.54 and a 52 week high of $5.35. The firm has a 50-day moving average of $4.86 and a 200 day moving average of $4.86.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 74.25% and a negative net margin of 485.71%. The company had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. During the same period in the previous year, the business earned ($0.11) EPS. TherapeuticsMD’s revenue for the quarter was down 3.4% compared to the same quarter last year. On average, analysts anticipate that TherapeuticsMD will post ($0.44) EPS for the current year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.